Ligand Pharmaceuticals Inc (LGND.OQ)
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|67||2017||Non-Executive Independent Chairman of the Board|
|44||2015||President, Chief Operating Officer|
|47||2015||Chief Executive Officer, Director|
|42||2015||Chief Financial Officer, Vice President - Finance|
|48||2007||Vice President, General Counsel, Secretary|
- BRIEF-Ligand Pharma reaffirms 2017 revenue guidance between $134 mln and $136 mln
- BRIEF-Ligand Pharmaceuticals says signed license and supply agreement via subsidiary with Meridian Laboratories
- BRIEF-Ligand Q3 adjusted earnings per share $0.69
- BRIEF-Ligand to acquire Crystal Bioscience
- BRIEF-Ligand announces top-line results from Phase 2 study of LGD-6972 in patients with Type 2 diabetes